This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
In the Federal Register, Feb 9, 1973, the Food and Drug Administration (FDA) published a notice to withdraw from the market certain antitussive combinations. Named in the withdrawal notice are the following preparations:
Novrad With ASA
Coricidin With Codeine Phosphate
Phenergan Expectorant With Codeine
Phenergan VC Expectorant
Phenergan VC Expectorant With Codeine
Pediatric Phenergan Expectorant
Phenergan Expectorant Troches
Phenergan Expectorant Troches With Codeine
Pyribenzamine Expectorant With Codeine and Ephedrine
However, other products of similar compositions will also be affected even though they are not specifically cited.
The FDA is basing this action on regulations established by the 1962 Harris-Kefauver amendments to the Food, Drug, and Cosmetic Act of 1938 and on the National Academy
Barclay WR. Antitussives in Jeopardy. JAMA. 1973;224(5):621-622. doi:10.1001/jama.1973.03220180041012